BHARAT IMMUNOLOGICALS (India) Financial Diagnostics

BIBCL -- India Stock  

INR 6.50  0.80  10.96%

BHARAT IMMUNOLOGICALS BIOLOG price decrease over the last few months could raise concerns from investors as the firm closed today at a share price of 6.4 on 7471.000 in volume. The company executives were not very successful in positioning the firm components to exploit market volatility in July. However, diversifying your holdings with BHARAT IMMUNOLOGICALS or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 4.3387. This high volatility is attributed to the latest market swings and not so good earning reports for some of the BHARAT IMMUNOLOGICALS partners. This diagnostics interface makes it easy to digest most current publicly released information about BHARAT IMMUNOLOGICALS as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis BHARAT IMMUNOLOGICALS price relationship with some important fundamental indicators such as market cap and management efficiency. Check also Trending Equities.


The company has price-to-book (P/B) ratio of 0.74. Some equities with similar Price to Book (P/B) outperform the market in the long run. BHARAT IMMUNOLOGICALS has Price/Earnings (P/E) ratio of 262.88. The entity recorded loss per share of 1.29. The firm had not issued any dividends in recent years. Bharat Immunologicals Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. The company was founded in 1989 and is based in Bulandshahr, India. BHARAT IMMUNOLOGICALS operates under Biotechnology classification in India and is traded on Bombay Stock Exchange. For more info on BHARAT IMUNO(BSE please contact the company at 91 57 3223 8757 or go to


BHARAT IMMUNOLOGICALS is not yet fully synchronised with the market data
BHARAT IMMUNOLOGICALS generates negative expected return over the last 30 days
BHARAT IMMUNOLOGICALS has high historical volatility and very poor performance
BHARAT IMMUNOLOGICALS has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 836.45M. Net Loss for the year was (55.57M) with profit before overhead, payroll, taxes, and interest of 103.65M.

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 252.17M.


The company has Profit Margin (PM) of (6.64) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (11.0) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.11.

Management Efficiency

BHARAT IMMUNOLOGICALS has return on total asset (ROA) of (9.86) % which means that it has lost $9.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (10.18) % meaning that it generated substantial loss on money invested by shareholders.

BHARAT IMMUNOLOGICALS Technical and Predictive Indicators

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
Check also Trending Equities. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.